Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69477 | 0.90 | ALPL (0.33) | PDGFRBKDR | |
| SCHEMBL11978298 | 0.81 | PIK3CA (0.34) | PDGFRBKDRAAK1 | |
| SCHEMBL3145752 | 0.78 | PIK3CA (0.37) | — | |
| SCHEMBL3136789 | 0.77 | PIK3CA (0.38) | PDGFRBKDRAAK1 | |
| SCHEMBL24215357 | 0.75 | ALPL (0.37) | AAK1 | |
| SCHEMBL15181587 | 0.75 | PDGFRB (0.33) | PDGFRBKDR | |
| SCHEMBL26916536 | 0.73 | NUDT1 (0.35) | PDGFRBKDR | |
| SCHEMBL26916529 | 0.73 | NUDT1 (0.35) | PDGFRBKDR | |
| SCHEMBL29273486 | 0.71 | KDM4C (0.37) | — | |
| SCHEMBL31272411 | 0.70 | PDGFRB (0.38) | PDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | PDGFRB 2417/4885KDR 1094/4885AAK1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.